基本情報
- CAS
10030-90-7- 標準SMILES
O=C([O-])CCC(=O)[O-].[Fe+2]- InChIKey
MDXRFOWKIZPNTA-UHFFFAOYSA-L- 分子式
- C4H4FeO4
- 平均分子量
- 171.92 g/mol
- 単同位体質量
- 171.94589611
概要
RN given refers to Fe(+2)(1:1) salt; important as iron supplement
名称と識別子
- 優先名称
- Ferrous succinate
- IUPAC
- butanedioate;iron(2+)
- 現地名
- こはく酸鉄(II)
- 英語名
- iron succinate
- 分子式
- C4H4FeO4
- 分子量
- 171.91716
名称と別名
Ferrous succinate10030-90-7Butanedioic acid, iron(2+) salt (1:1)Ferrlecit 2FERROMYNIron succinate (fe(o4c4h4))818ZYK7N91butanedioic acid, iron (+2) saltferrosuccinateRefChem:921575233-082-3Iron succinate
名称をさらに表示
ブタン二酸鉄(II)こはく酸鉄(II)コハク酸鉄 (II)1,3-ジオキサ-2-フェラシクロヘプタン-4,7-ジオンEisensuccinatEisensuccinat CASIron(II)-succinateEisen(II)-succinatferrous succinic acidbutanedioate,iron(2+)iron succinate USP/EP/BPSuccinic acid iron(II) saltFERROUSSUCCINATE,18.5%,POWDER
iron(II) succinatebutanedioate;iron(2+)Succinic acid iron(II) salt;Succinic acid iron(II) saltUNII-818ZYK7N91EINECS 233-082-3Ferplex (TN)SCHEMBL275423FERROUS SUCCINATE [MI]
データベース識別子
- CAS
10030-90-7- PubChem CID
- 10464762
- DTXSID
DTXSID101373453- ChEMBL
CHEMBL3707232- UNII
- 818ZYK7N91
- EC Number
- 233-082-3
- Nikkaji
- J62.812C
物性
構造計算による物性
- 極性表面積
- 80.3 Ų
- 水素結合供与体数
- 0
- 水素結合受容体数
- 4
- 回転可能結合数
- 1
- 重原子数
- 9
- 形式電荷
- 0
- 複雑度
- 81.6
物理化学的性質
- InChI
- InChI=1S/C4H6O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H2,(H,5,6)(H,7,8);/q;+2/p-2
- InChIKey
- MDXRFOWKIZPNTA-UHFFFAOYSA-L
- SMILES
- C1(=O)O[Fe]OC(=O)CC1
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS ClassificationNot Classified
危険有害性情報
Regulatory InformationChemical: Butanedioic acid, iron(2+) salt (1:1)
Hazard Classes and CategoriesNot Classified
化学と産業
薬理情報
ATC Code
B - Blood and blood forming organs
QB - Blood and blood forming organs
PharmacodynamicsThe major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.
Mechanism of ActionIron is necessary for the production of hemoglobin. Iron-deficiency can lead to decreased production of hemoglobin and a microcytic, hypochromic anemia.
MeSH Pharmacological ClassificationAgents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias.
Absorption, Distribution and Excretion
The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.
応用分野
使用Iron succinate is an oral iron supplement for the treatment of iron deficiency (ID). Iron succinate increases ferritin and transferrin saturation in non-anaemic heart failure and iron deficient patients and can significantly increase iron uptake in patients with heart failure (HF), nearly doubling ferritin levels and increasing TSAT. Patients with HFrEF or HFpEF appear to have a similar response[1].
サプライヤー
読み込み中…
公開中の見積依頼
読み込み中…
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…